Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FCN 437

Next Previous
X
Search
Drug Profile

FCN 437

Alternative Names: FCN-437; FCN-437c

Latest Information Update: 28 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Fochon Pharmaceutical
  • Developer Ahon Pharmaceutical; Chongqing Fochon Pharmaceutical; Shanghai Fosun Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration HER2 negative breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 27 Sep 2024 Ahon Pharmaceutical completes a phase I safety and pharmacokinetic study in healthy subjects in China (PO, capsule) (NCT06620731)
  • 30 Nov 2023 Preregistration for HER2-negative-breast-cancer (Late-stage disease, Second-line therapy or greater) in China (PO) prior to November 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top